| Yes‐associated protein is an independent prognostic marker in hepatocellular carcinoma MZ Xu, TJ Yao, NPY Lee, IOL Ng, YT Chan, L Zender, SW Lowe, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2009 | 577 | 2009 |
| AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma MZ Xu, SW Chan, AM Liu, KF Wong, ST Fan, J Chen, RT Poon, L Zender, ... Oncogene 30 (10), 1229-1240, 2011 | 261 | 2011 |
| Circulating Lamin B1 (LMNB1) biomarker detects early stages of liver cancer in patients S Sun, MZ Xu, RT Poon, PJ Day, JM Luk Journal of proteome research 9 (1), 70-78, 2010 | 183 | 2010 |
| miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma AM Liu, Z Xu, FH Shek, KF Wong, NP Lee, RT Poon, J Chen, JM Luk PloS one 9 (1), e86872, 2014 | 149 | 2014 |
| Targeting cadherin‐17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma LX Liu, NP Lee, VW Chan, W Xue, L Zender, C Zhang, M Mao, H Dai, ... Hepatology 50 (5), 1453-1463, 2009 | 146 | 2009 |
| Targeting YAP and Hippo signaling pathway in liver cancer AM Liu, MZ Xu, J Chen, RT Poon, JM Luk Expert opinion on therapeutic targets 14 (8), 855-868, 2010 | 116 | 2010 |
| Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma X Huo, QI Zhang, AM Liu, C Tang, Y Gong, J Bian, JM Luk, Z Xu, J Chen Oncology reports 29 (2), 840-846, 2013 | 96 | 2013 |
| Common genetic variation in ETV6 is associated with colorectal cancer susceptibility M Wang, D Gu, M Du, Z Xu, S Zhang, L Zhu, J Lu, R Zhang, J Xing, X Miao, ... Nature Communications 7 (1), 11478, 2016 | 83 | 2016 |
| Clinical significance of the expression of DNA methyltransferase proteins in gastric cancer J Yang, X Wei, Q Wu, Z Xu, D Gu, Y Jin, Y Shen, H Huang, H Fan, J Chen Molecular medicine reports 4 (6), 1139-1143, 2011 | 78 | 2011 |
| E2F1-induced upregulation of long noncoding RNA LINC00668 predicts a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically silencing of CKIs E Zhang, D Yin, L Han, X He, X Si, W Chen, R Xia, T Xu, D Gu, W De, ... Oncotarget 7 (17), 23212, 2016 | 70 | 2016 |
| Clinical significance of SOD2 and GSTP1 gene polymorphisms in Chinese patients with gastric cancer Z Xu, H Zhu, JM Luk, D Wu, D Gu, W Gong, Y Tan, J Zhou, J Tang, ... Cancer 118 (22), 5489-5496, 2012 | 68 | 2012 |
| Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma KF Wong, AM Liu, W Hong, Z Xu, JM Luk Oncotarget 7 (47), 77683, 2016 | 62 | 2016 |
| Clinical significance of expression of Hint1 and potential epigenetic mechanism in gastric cancer H Huang, X Wei, X Su, F Qiao, Z Xu, D Gu, H Fan, J Chen International journal of oncology 38 (6), 1557-1564, 2011 | 52 | 2011 |
| Frequent KIT mutations in human gastrointestinal stromal tumors Z Xu, X Huo, C Tang, H Ye, V Nandakumar, F Lou, D Zhang, S Jiang, ... Scientific reports 4 (1), 5907, 2014 | 44 | 2014 |
| Genetic variant in 8q24 is associated with prognosis for gastric cancer in a C hinese population G Ma, D Gu, C Lv, H Chu, Z Xu, N Tong, M Wang, C Tang, Y Xu, Z Zhang, ... Journal of gastroenterology and hepatology 30 (4), 689-695, 2015 | 43 | 2015 |
| Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma NPY Lee, K Leung, N Cheung, BY Lam, MZ Xu, PC Sham, GK Lau, ... Proteomics 8 (10), 2136-2149, 2008 | 39 | 2008 |
| Comparative efficacy and safety of palonosetron with the first 5‐HT3 receptor antagonists for the chemotherapy‐induced nausea and vomiting: a meta‐analysis Y Jin, W Sun, D Gu, J Yang, Z Xu, J Chen European journal of cancer care 22 (1), 41-50, 2013 | 38 | 2013 |
| An update on targeting Hippo-YAP signaling in liver cancer AM Liu, Z Xu, JM Luk Expert opinion on therapeutic targets 16 (3), 243-247, 2012 | 34 | 2012 |
| Clinical significance of ALDH2 rs671 polymorphism in esophageal cancer: evidence from 31 case-control studies T Zhao, C Wang, L Shen, D Gu, Z Xu, X Zhang, Y Xu, J Chen OncoTargets and therapy, 649-659, 2015 | 31 | 2015 |
| Optimizing the treatment schedule of radiotherapy combined with anti-PD-1/PD-L1 immunotherapy in metastatic cancers Y Kong, Y Ma, X Zhao, J Pan, Z Xu, L Zhang Frontiers in Oncology 11, 638873, 2021 | 29 | 2021 |
